{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:33Z","timestamp":1740108273398,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"none"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00198-021-05933-3","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T02:02:51Z","timestamp":1617328971000},"page":"2105-2109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term evaluation of anabolic and anti-resorptive agents in adults with familial osteoporosis due to pro205ala variant of the col1a1 gene"],"prefix":"10.1007","volume":"32","author":[{"given":"H.K.","family":"Datta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5060-4214","authenticated-orcid":false,"given":"S.P.","family":"Tuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"5933_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC (2016) Osteogenesis imperfecta. Lancet 387:1657\u20131671","journal-title":"Lancet"},{"issue":"17052","key":"5933_CR2","first-page":"1","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, B\u00e4chinger HP et al (2017) Osteogenesis imperfecta. Nat Rev Dis Primers 3(17052):1\u201319","journal-title":"Nat Rev Dis Primers"},{"key":"5933_CR3","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1016\/S0021-9258(18)48196-3","volume":"262","author":"JF Bateman","year":"1987","unstructured":"Bateman JF, Chan D, Walker ID, Rogers JG, Cole WG (1987) Lethal perinatal osteogenesis imperfecta due to the substitution of arginine for glycine at residue 391 of the alpha 1(I) chain of type I collagen. J Biol Chem 262:7021\u20137027","journal-title":"J Biol Chem"},{"key":"5933_CR4","doi-asserted-by":"publisher","first-page":"7855","DOI":"10.1016\/S0021-9258(18)68576-X","volume":"263","author":"PH Byers","year":"1988","unstructured":"Byers PH, Starman BJ, Cohn DH, Horwitz AL (1988) A novel mutation causes a perinatal lethal form of osteogenesis imperfecta. An insertion in one alpha 1(I) collagen allele (COL1A1). J Biol Chem 263:7855\u20137861","journal-title":"J Biol Chem"},{"key":"5933_CR5","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.1073\/pnas.83.16.6045","volume":"83","author":"DH Cohn","year":"1986","unstructured":"Cohn DH, Byers PH, Steinmann B, Gelinas RE (1986) Lethal osteogenesis imperfecta resulting from a single nucleotide change in one human pro alpha 1(I) collagen allele. Proc Natl Acad of Sci USA 83:6045\u20136047","journal-title":"Proc Natl Acad of Sci USA"},{"key":"5933_CR6","first-page":"591","volume":"46","author":"DH Cohn","year":"1990","unstructured":"Cohn DH, Starman BJ, Blumberg B, Byers PH (1990) Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a dominant mutation in a human type I collagen gene (COL1A1). Am J Hum Genet 46:591\u2013601","journal-title":"Am J Hum Genet"},{"key":"5933_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/jmg.27.9.545","volume":"27","author":"WG Cole","year":"1990","unstructured":"Cole WG, Campbell PE, Rogers JG, Bateman JF (1990) The clinical features of osteogenesis imperfecta resulting from a non-functional carboxy terminal pro alpha 1(I) propeptide of type I procollagen and a severe deficiency of normal type I collagen in tissues. J Med Genet 27:545\u2013551","journal-title":"J Med Genet"},{"key":"5933_CR8","first-page":"670","volume":"47","author":"CD Constantinou","year":"1990","unstructured":"Constantinou CD, Pack M, Young SB, Prockop DJ (1990) Phenotypic heterogeneity in osteogenesis imperfecta: the mildly affected mother of a proband with a lethal variant has the same mutation substituting cysteine for alpha 1-glycine 904 in a type I procollagen gene (COL1A1). Am J Hum Genet 47:670\u2013679","journal-title":"Am J Hum Genet"},{"key":"5933_CR9","doi-asserted-by":"publisher","first-page":"15608","DOI":"10.1016\/S0021-9258(18)98449-8","volume":"266","author":"T Tsuneyoshi","year":"1991","unstructured":"Tsuneyoshi T, Westerhausen A, Constantinou CD, Prockop DJ (1991) Substitutions for glycine alpha 1-637 and glycine alpha 2-694 of type I procollagen in lethal osteogenesis imperfecta. The conformational strain on the triple helix introduced by a glycine substitution can be transmitted along the helix. J Biol Chem 266:15608\u201315613","journal-title":"J Biol Chem"},{"key":"5933_CR10","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/S0021-9258(18)52374-7","volume":"266","author":"M Valli","year":"1991","unstructured":"Valli M, Mottes M, Tenni R, Sangalli A, Gomez Lira M, Rossi A, Antoniazzi F, Cetta G, Pignatti PF (1991) A de novo G to T transversion in a pro-alpha 1 (I) collagen gene for a moderate case of osteogenesis imperfecta. Substitution of cysteine for glycine 178 in the triple helical domain. J Biol Chem 266:1872\u20131878","journal-title":"J Biol Chem"},{"key":"5933_CR11","doi-asserted-by":"publisher","first-page":"14737","DOI":"10.1016\/S0021-9258(18)47857-X","volume":"262","author":"BE Vogel","year":"1987","unstructured":"Vogel BE, Minor RR, Freund M, Prockop DJ (1987) A point mutation in a type I procollagen gene converts glycine 748 of the alpha 1 chain to cysteine and destabilizes the triple helix in a lethal variant of osteogenesis imperfecta. J Biol Chem 262:14737\u201314744","journal-title":"J Biol Chem"},{"key":"5933_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ajmg.1320450214","volume":"45","author":"MC Willing","year":"1993","unstructured":"Willing MC, Pruchno CJ, Byers PH (1993) Molecular heterogeneity in osteogenesis imperfecta type I. Am J Med Genet 45:223\u2013227","journal-title":"Am J Med Genet"},{"key":"5933_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jmg.32.9.697","volume":"32","author":"MC Willing","year":"1995","unstructured":"Willing MC, Slayton RL, Pitts SH, Deschenes SP (1995) Absence of mutations in the promoter of the COL1A1 gene of type I collagen in patients with osteogenesis imperfecta type I. J Med Genet 32:697\u2013700","journal-title":"J Med Genet"},{"key":"5933_CR14","first-page":"1186","volume":"48","author":"JP Zhuang","year":"1991","unstructured":"Zhuang JP, Constantinou CD, Ganguly A, Prockop DJ (1991) A single base mutation in type I procollagen (COL1A1) that converts glycine alpha 1-541 to aspartate in a lethal variant of osteogenesis imperfecta: detection of the mutation with a carbodiimide reaction of DNA heteroduplexes and direct sequencing of products of the PCR. Am J Hum Genet 48:1186\u20131191","journal-title":"Am J Hum Genet"},{"key":"5933_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/(SICI)1096-8628(19960111)61:2<111::AID-AJMG1>3.0.CO;2-#","volume":"61","author":"J Zhuang","year":"1996","unstructured":"Zhuang J, Tromp G, Kuivaniemi H, Castells S, Prockop DJ (1996) Substitution of arginine for glycine at position 154 of the alpha 1 chain of type I collagen in a variant of osteogenesis imperfecta: comparison to previous cases with the same mutation. Am J Med Genet 61:111\u2013116","journal-title":"Am J Med Genet"},{"key":"5933_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/jbmr.5650090618","volume":"9","author":"LD Spotila","year":"1994","unstructured":"Spotila LD, Colige A, Sereda L, Constantinou-Deltas CD, Whyte MP, Riggs BL, Shaker JL, Spector TD, Hume E, Olsen N (1994) Mutation analysis of coding sequences for type I procollagen in individuals with low bone density. J Bone Miner Res 9:923\u2013932","journal-title":"J Bone Miner Res"},{"key":"5933_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.1380020308","volume":"2","author":"M Mottes","year":"1993","unstructured":"Mottes M, Gomez Lira MM, Valli M et al (1993) Paternal mosaicism for a COL1A1 dominant mutation (alpha 1 Ser-415) causes recurrent osteogenesis imperfecta. Hum Mutat 2:196\u2013204","journal-title":"Hum Mutat"},{"key":"5933_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES, Shapiro J, Veith S et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124:491\u2013498","journal-title":"J Clin Invest"},{"key":"5933_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","volume":"87","author":"JR Shapiro","year":"2010","unstructured":"Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C (2010) Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 87:120\u2013129","journal-title":"Calcif Tissue Int"},{"key":"5933_CR20","first-page":"1465","volume":"10","author":"K Dwan","year":"2016","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2016) Bisphosphonate therapy for osteogegensis imperfecta. Cochrane Database Syst Rev 10:1465\u20131858","journal-title":"Cochrane Database Syst Rev"},{"key":"5933_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-017-0236-9","volume":"100","author":"O Viapana","year":"2017","unstructured":"Viapana O, Idolazzi L, Fassio A et al (2017) Long term effects of neridronate in adults with osteogenesis imperfecta: an observational 3 year Italian study. Calcif Tissue Int 100:341\u2013347","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"5933_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.endinu.2018.05.015","volume":"66","author":"P de Paz","year":"2019","unstructured":"de Paz P, Rosado Sierra JA, Perez Blanco C et al (2019) Acute and long term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational stuyd with 5 years follow up. Endocrinol Diabetes Nutr 66(2):108\u2013116","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"1","key":"5933_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","volume":"23","author":"LA Bradbury","year":"2012","unstructured":"Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JAH, Russell RGG, Brown MA, Duncan EL (2012) Risedronate in adults with osteogenesis imperfecta type 1: increased bone mineral desnity and decreased bone tunrover, but high fracture rate persists. Osteoporos Int 23(1):285\u2013294","journal-title":"Osteoporos Int"},{"issue":"11","key":"5933_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.4158\/EP151184.OR","volume":"22","author":"X Xiao-Jie","year":"2016","unstructured":"Xiao-Jie X, Dou-Dou M, Fang LV et al (2016) The clinical characteristics and efficacy of bisphopshonates in adult patients with osteogenesis imperfecta. Endocr Pract 22(11):1267\u20131276","journal-title":"Endocr Pract"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05933-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T03:52:39Z","timestamp":1634097159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05933-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5933"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05933-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}